Analysts Set Cellectis S.A. (NASDAQ:CLLS) PT at $34.67

Shares of Cellectis S.A. (NASDAQ:CLLS) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $34.67.

CLLS has been the subject of several analyst reports. William Blair reaffirmed a “buy” rating on shares of Cellectis in a report on Tuesday, June 1st. Oppenheimer started coverage on shares of Cellectis in a research note on Thursday, June 3rd. They issued a “buy” rating and a $33.00 target price on the stock. Guggenheim reiterated a “neutral” rating on shares of Cellectis in a research note on Tuesday, May 4th. Robert W. Baird reiterated a “buy” rating and issued a $39.00 target price on shares of Cellectis in a research note on Thursday, May 27th. Finally, Zacks Investment Research cut shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Monday, May 17th.

CLLS traded up $0.09 on Tuesday, hitting $15.39. The company’s stock had a trading volume of 4,283 shares, compared to its average volume of 361,830. The stock’s 50 day simple moving average is $17.23. The stock has a market cap of $699.64 million, a price-to-earnings ratio of -5.67 and a beta of 2.38. Cellectis has a 12 month low of $14.18 and a 12 month high of $34.71. The company has a current ratio of 5.81, a quick ratio of 5.69 and a debt-to-equity ratio of 0.10.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.54. Cellectis had a negative net margin of 200.21% and a negative return on equity of 36.24%. Research analysts anticipate that Cellectis will post -2.49 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Cellectis during the 1st quarter valued at $39,000. US Bancorp DE raised its position in shares of Cellectis by 25.7% during the 4th quarter. US Bancorp DE now owns 1,964 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 402 shares in the last quarter. RMR Wealth Builders purchased a new stake in shares of Cellectis during the 4th quarter valued at $55,000. Barclays PLC raised its position in shares of Cellectis by 833.6% during the 4th quarter. Barclays PLC now owns 4,528 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 4,043 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Cellectis during the 4th quarter valued at $203,000. Hedge funds and other institutional investors own 33.68% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Story: Equity Income

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.